slide-01-title

Bethel Digital Therapeutics

The Operating System for Pediatric Care.

TALK 3D (Core)AI Storybook (Growth)Virtual Reality (Alpha)Lancet PublishedVertical MedTech PlatformSeries A Ready
The Platform Strategy
slide-02-market-context

The Care Gap

0%
China Language Delays Prevalence
Wu et al. (2023) The Lancet Regional Health
>0
Children needing care
Underserved Families
0:2,000
Therapist Availability
Severe Shortage
$0/mo
Family Spend
High Willingness to Pay

Digital Care is the only scalable bridge.

slide-03-the-platform

The Bethel OS Architecture

One Platform. Three Integrated Layers.

The Foundation (Base)

Layer 1: The Clinical Core

Proprietary R&D Engine

Led by Dr. Lucy Liu & 10+ global experts.

slide-04-moat-authority

The Trust Barrier

0+
Tier-3A Hospital Partners
0+ Years
Clinical Data Advantage
Zero
Cost to acquire Credibility
West China HospitalShanghai Children Medical CenterPeking Union Medical College HospitalBeijing Children's HospitalChongqing Children's HospitalShenzhen Children's HospitalWuhan Tongji HospitalNanjing Maternity amd Child Health Care HospitalBeijing Tongren HospitalCapital Institute of Pediatrics
Trust Transfer Engine
slide-05-talk3d-deep-dive

Engine 1: TALK 3D - The Core System

Language, Social & Communication Development

DREAM® Assessment (China Standard)
Automated IEP Generation
Home-Clinic Data Sync
Gamified Lessons
Proprietary Normative Data
Clinical Guardrails (AI-Guided)
DREAM® Used in 300+ Class III Hospitals
slide-06-layer1-traction

TALK 3D: Unit Economics

Monetizing the 'Hospital Halo Effect'

$0
Entry Annual Revenue
Low-friction 'Land' price
$0
Pilot Unit Yield (Mo. 1)
Chengdu Pilot (4x Expansion)
0%
Blended Gross Margin
Software-like economics
0:1
Return on Acq. Cost
Driven by Zero-Cost Trust

Zero-Cost Credibility: Clinics buy us because Hospitals use us.

slide-07-talk3d-financials

TALK 3D: Financial Scale

Clinical trust converts into distributor-led compounding revenue.

$6.7M
$5.0M
$3.4M
$1.7M
$0.0M
$1.1M USD

2026

$1.9M USD

2027

$3.6M USD

2028

$5.0M USD

2029

$6.7M USD

2030

6.1x projected revenue expansion from 2026 to 2030.

Steady, recurring revenue compounds as the installed base deepens.

slide-08-dreamolia-deep-dive

Engine 2: DREAMOLIA® - AI Storybook

Precision Neurodevelopmental Intervention

Toy-Based Pedagogy

Transforms the child's real-world toy into a digital hero to anchor attention (ADHD specific).

Parental Voice Clone

Uses 'Parentese' prosody to deliver therapy in the parent's voice, reinforcing emotional safety.

Dynamic Text (DTP)

Reduces 'visual crowding' for dyslexic readers by highlighting text in sync with audio.

Generative Social Grammar

Teaches complex social interactions and 'Theory of Mind' through personalized storytelling.

slide-09-dreamolia-product-moat

DREAMOLIA®: Precision vs Generic AI

Why clinical guardrails outperform raw generation

Uncontrolled Generation

Generic AI

Broad and shallow outputs

Higher hallucination risk

No pathology-specific guidance

Unsafe for therapy-critical decisions.

Clinically Guided Generation

Bethel AI

Pathology-specific response shaping

Clinical Logic Layer validation

Therapeutically aligned output

Built for real-world pediatric intervention.

Every generated intervention is filtered through clinical guardrails before delivery.

We sell safety, not just generation.

slide-10-dreamolia-valuation

Valuing DREAMOLIA®

Benchmarking DREAMOLIA® against engagement + wellness leaders

$0M+
Duolingo
Consumer Learning | Gamified efficacy
$0M+
Calm
Mental Wellness | Subscription health

DREAMOLIA® combines Duolingo-grade engagement with Calm-like health monetization.

slide-11-compliance-security

Compliance & Security Architecture

Dual-Stack Isolation

Global

Global Stack

AWS + US LLMs (Global Data)

China

China Stack

AliCloud + Local LLMs (Domestic Data)

Zero Cross-Border Personal Identifiable Information (PII) Transfer

slide-12-floreo-deep-dive

Engine 3: Floreo VR Partnership

Exclusive China Joint Venture

Localizing the world’s leading VR behavioral therapy for immediate clinical deployment.

Pico Localization

Port Floreo’s Unity therapy stack to China-native Pico hardware.

Hainan Green Channel

Medical Pilot Zone allowing fast-track import, bypassing multi-year approval cycles.

Hospital Distribution

Leverage Bethel’s existing Tier-3A network for rapid rollout.

FDA Breakthrough Device

Leverage global accreditation for local authority.

Not reseller economics: exclusive JV control + local execution advantage.

slide-13-talk3d-economics

Revenue Expansion: $24K Per Clinic

Land once at $6K, then stack three module expansions to compound revenue.

Deployment Base

COTS (Commercial Off-The-Shelf)

Standard iPad & Pico VR

Proprietary Kiosk Mode (MDM)

Zero Manufacturing Risk

Unit Economics Expansion

$0K Revenue / Clinic

4x Revenue expansion from one installed clinic relationship.

$24K
$18K
$12K
$6K
$0K
$6K
$5K
$5K
$8K
Total: $24K

Per Clinic Annual Revenue

Land + Expand Sequence

Land: Core Bethel DREAM®

$6K

Anchor subscription

Expand 1: TALK-3D Home Data-Sync iPads

$5K

Data continuity upsell

Expand 2: DREAMOLIA® AI Storybook

$5K

High-margin parent module

Expand 3: Floreo VR

$8K

JV revenue-share upside

4x Revenue expansion from one installed clinic relationship.

slide-14-revenue-bridge

Total Revenue Potential (2026-2030)

One installed base, four product streams, compounding year by year.

$21.2M
$15.9M
$10.6M
$5.30M
$0

$1.94M

2026

$4.35M

2027

$8.43M

2028

$13.8M

2029

$21.2M

2030

Bethel OS

TALK-3D

DREAMOLIA®

FloreoVR

2030 Total Revenue

$0M

Revenue scales from $1.94M (2026) to $21.18M (2030), a 10.9x expansion.

Growth is driven by additional services on the same clinical footprint.

slide-15-team-execution

World-Class Team

Our team bridges the gap between Western science and Chinese practice.

BCBA & CCC-SLPs: Full-time, US-certified experts on staff.

Linguists: Experts in Mandarin language acquisition nuances.

Verifiable Recognition:

  • ASHA Centennial Session Presenters
  • Published authors (Textbooks/SCI Publications)
  • University of Texas at Dallas (UTD)

Clinical DNA + Tech Scale

slide-16-the-ask

Bethel’s established network already spans 300 top Tier-3A hospitals across China.

Return on Investment: The 2030 Case

Safety in Domestic Core + Upside in Global Scale

Entry Anchor Valuation
$0M (Series A)
2030 Target Valuation
$0M (2030 Target)
2030 Target Return Profile
0x ROI, 55% IRR

Value: TALK 3D (Domestic Core)

$0M
$6.7M Rev5x Multiple (Base Case)

Value: AI Storybook (Global)

$0M
$7.1M Rev12x Multiple (AI Platform)

Value: Floreo JV (Import)

$0M
$7.9M Rev6x Multiple (MedTech)
slide-17-alignment-protocol

Our Commitment: Skin in the Game

We put Shareholders and Investors BEFORE ourselves.

Matching Investment(1:2 Ratio)

We invest $1 of personal capital for every $2 of outside capital.

Subordinated Equity(First-Loss Position)

In a downside scenario, Founder Common Stock is liquidated *before* Investor Preferred Stock.

Liquidity Sequence(Last-Out Clause)

We will NOT cash out until AFTER all investors who want to exit have successfully exited.

— Dr. Lucy Liu & Daniel Ng, Series A Closing

Radical Founder-Investor Alignment. We are not here to play startup. We are here to build a legacy.

If this aligns with your investment mandate, I welcome a direct note.

[email protected]www.ourbethel.com